Varenicline and cardiovascular risk
The smoking cessation aid varenicline (Chantix, Pfizer) may increase the risk of cardiovascular events in adults with cardiovascular disease, according to a recent FDA safety announcement.
The smoking cessation aid varenicline (Chantix, Pfizer) may increase the risk of cardiovascular events in adults with cardiovascular disease, according to a recent FDA safety announcement.
The announcement follows the results of a meta-analysis of 15 Pfizer-sponsored, randomized double-blind, placebo-controlled clinical trials that included 7,002 patients, which was conducted to assess the occurrence and timing of major adverse cardiovascular events.
Researchers found that, within 30 days of treatment, patients taking varenicline were slightly more likely than patients taking placebo to experience a major adverse event, reported as a combined outcome of cardiovascular-related death, nonfatal heart attack, and nonfatal stroke (varenicline, 0.31% [13/4190]; placebo, 0.21% [6/2812]). FDA notes that the events were uncommon in both groups, and the increased risk was not statistically significant; however multiple data analyses consistently demonstrated a higher occurrence of these events in patients taking varenicline.
FDA reports that the Warnings and Precautions section of the Chantix label has been updated to include the results of the new data.
“It is important to note that smoking is a major risk factor for cardiovascular disease, and Chantix is effective in helping patients to quit smoking and abstain from it for as long as 1 year. The health benefits of quitting smoking are immediate and substantial,” FDA notes. But, the organization advises healthcare professionals to weigh risks of treatment against the benefits for each patient.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
CVS Caremark Makes Changes in Diabetes Coverage for 2025
Published: November 25th 2024 | Updated: November 25th 2024CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
Read More
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
